Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2012

View Archived Issues

Plant-based platform developed for production of antimalarial drug

Takeda identifies benzazepine derivatives for treatment of obesity

Selective GlyT2 inhibitor shows promising analgesic effects in vivo

Mochida reports potent in vivo analgesic activity for proprietary drug

European team generates water-stable, helicate-like products as potential antimicrobials

Oleanolic acid derivative shows promise in model of MS

New panthetheinase inhibitors presented to treat malaria

Exonhit discloses novel tubulin polymerization inhibitors

Boehringer Ingelheim synthesizes novel chemokine CCR2 receptor antagonists

GlaxoSmithKline enrolling toddlers in phase I pneumococcal vaccine trial

Recruitment begins in phase III BEACON study

New phosphodiesterase inhibitors prepared at IntraCellular Therapies

Cardiolynx patents new pioglitazone derivatives

Novel peptide conjugates for bacterial infections designed in Canada

Lundbeck launches antiepileptic tablet in U.S.

Resubmitted pixantrone NDA to be reviewed by FDA's ODAC

New alpha-glucosidase inhibitors developed in Spain

Phase IIb trial of photodynamic therapy for cervical intraepithelial neoplasia advances

Phylogica enters new collaboration involving Phylomer peptide platform

Enrollment in phase II KRN-321 study begins in Japan

Agile Therapeutics completes phase III program for contraceptive patch

Advaxis to raise additional funding with sale of convertible promissory notes

Tivozanib superior to sorafenib in phase III study

Alnylam reports encouraging preclinical data on RNAi therapeutic for Huntington's disease

Glenmark begins pivotal study of antidiarrheal drug in India

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026